FDA Approval of Heron Therapeutics' (HRTX) Sustol Removes Major Overhang - Analyst

August 10, 2016 11:14 AM EDT
Get Alerts HRTX Hot Sheet
Price: $12.95 +0.39%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 9
Trade HRTX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Leerink affirms Heron Therapeutics (Nasdaq: HRTX) at Outperform with a price target of $33 following FDA approval of Sustol for treatment of chemo induced nausea and vomiting.

Analyst Jason Gerberry commented today: We are still reviewing the package insert, but Sustol appears to have gotten a favorable label on balance and the approval removes a major overhang on the stock. In terms of key label claims, Sustol was approved for acute and delayed MEC (moderate chemo regimens) and acute/delayed AC regimens (anthracycline and cyclophosphamide), which are a subset of HEC (highly emetogenic) chemo regimens. While HRTX did not get a broad delayed HEC indication, the company believes an indication for delayed AC will allow it to reach most of the HEC market. A conference call will be held at 9:00 A.M. EDT and we expect the focus of the call to be on commercial strategy, launch plans and market sizing. We reiterate our OP rating and we are encouraged to see Sustol get differentiated label claims relative to Easai’s Aloxi.

For an analyst ratings summary and ratings history on Heron Therapeutics click here. For more ratings news on Heron Therapeutics click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment